iShares Genomics Immunology and Healthcare ETF (IDNA) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores IDNA 2.5 out of 10 — highest on Return (5.0), lowest on Quality (0.4). Its ten largest holdings are 48% of the fund.
What stands out in IDNA's data
Genomics and healthcare innovators, from drug discovery to immunology.
Earnings margins trail those of most biotech peers — the fund's promise rests on future breakthroughs, not current profits.
EBITDA margin of 13.7% lags the category median of 20.5% and sits below its own historical median of 16.2%. Analysts project a 13.6% growth estimate ahead.
A satellite sleeve for portfolios that want exposure to genomics and early-stage drug discovery.
Why did IDNA move this week? It rose 1.2% in the week to October 9, 2026 — Moderna and Genmab A/S drove it
IDNA rose 1.2% in the week to October 9, 2026. The holdings that moved it most were Moderna (+18.4%), Genmab A/S (+8.0%) and Novavax (+21.9%); Twist Bioscience (−15.3%) pushed the other way.
How is IDNA rated? ETF Copilot scores iShares Genomics Immunology and Healthcare ETF (IDNA) 2.5 out of 10
As of October 9, 2026, ETF Copilot scores iShares Genomics Immunology and Healthcare ETF (IDNA) 2.5 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 2.5 / 10
- Growth: 2.6 / 10
- Risk: 0.8 / 10
- Quality: 0.4 / 10
- Return: 5.0 / 10
What's inside IDNA?
What's inside IDNA: Size (Large 42%, Mid 37%, Small 21%); Geography (International 33%, US 67%).
What are IDNA's top holdings? The ten largest are 48% of the fund
Moderna, Twist Bioscience, Iovance Biotherapeutics, Genmab, Revolution Medicines, Takeda Pharmaceutical, Merck, Immunitybio, Regeneron Pharmaceuticals and Bayer are IDNA's largest holdings, in that order.
More concentrated than 57% of Health & Biotech ETFs.
Half of IDNA's weight sits in its 11 largest positions, and once those weights are taken into account it behaves like 25 equally weighted holdings.
What is IDNA's expense ratio? 0.47% a year
As of October 9, 2026, IDNA charges 0.47% a year, yields 0.69% and holds $308M in assets across 58 positions.
| Measure | IDNA |
|---|---|
| Expense ratio | 0.47% |
| Dividend yield | 0.69% |
| Assets under management | $308M |
| Holdings | 58 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “iShares Genomics Immunology and Healthcare ETF (IDNA) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/idna
ETF Copilot Pro unlocks IDNA's price and what each holding weighs.
Try Pro free →